A child loses the ability to speak. Another develops epilepsy in infancy. A third has mild learning difficulties that don't become clear until school. For years, their families search for an answer. Some never find one. The disorder causing these symptoms was invisible — not because it's rare, but because nobody thought to look for it in the right place.
Researchers at the Icahn School of Medicine at Mount Sinai have identified it. Recessive ReNU2 syndrome is the most prevalent recessive neurodevelopmental disorder ever discovered, accounting for roughly 10 percent of all recessive NDD cases with a known genetic cause in the UK, according to a study published in Nature Genetics on March 30, 2026. It affects thousands in the United States alone and may involve hundreds of thousands globally.
The culprit is a gene called RNU2-2, which produces a molecule called U2-2 RNA. That RNA is a core part of the spliceosome — the cellular machinery that cuts out the non-coding portions of gene transcripts and stitches the protein-coding pieces together. U2-2 belongs to a class of small nuclear RNAs (snRNAs) that form the backbone of the spliceosome alongside U1, U2, U4, U5, and U6. Without enough U2-2 RNA, the spliceosome malfunctions, and neurodevelopment goes wrong in ways that vary widely from child to child: developmental delay, epilepsy, movement disorders, absent or limited speech, and in the most severe cases, progressive encephalopathy and early death.
The researchers found the association by applying a Bayesian statistical method called BeviMed to whole-genome sequencing data from the UK's 100,000 Genomes Project and the National Genomic Research Library. They compared 14,805 individuals with a neurodevelopmental disorder against 52,861 people without one. The result was a log Bayes factor of 18.2 — "very strong evidence" as the authors note, though that phrase undersells the number. They then used read-backed phasing across the tiny RNU2-2 gene — all 191 base pairs of it — to distinguish between patients who inherited one damaging variant from each parent and those with two damaging variants inherited together (compound heterozygosity).
Replication came from three independent cohorts: the Undiagnosed Diseases Network in the US, the Ospedale Pediatrico Bambino Gesù in Italy, and Erasmus MC in the Netherlands. The study identified 18 high-confidence cases with two damaging variants in trans, plus 13 lower-confidence compound heterozygous cases. The US cohort confirmed seven additional probands with matching inheritance patterns.
The biological consequence is a near-complete absence of U2-2 RNA in patient blood, confirmed by RNA sequencing. The correlation with severity runs in the right direction: patients with higher residual U2-2 RNA tend to have milder symptoms. "It appears that patients with higher — albeit still low — levels of U2-2 are less severely affected," Ernest Turro, the study's senior author, wrote. That observation points directly at a therapeutic strategy: supply the missing RNA.
What makes this prevalence finding striking is the inheritance pattern. The most common monogenic neurodevelopmental disorders tend to be dominant — one damaged copy is enough to cause disease, and new mutations keep replenishing the pool. Recessive disorders, which require two broken copies, typically stay rare because carriers are unaffected. Recessive ReNU2 syndrome breaks that rule. The researchers estimate it is roughly 60 percent as common as dominant ReNU syndrome in the UK. Aggregating across monoallelic and biallelic cases, the total ReNU2 syndrome burden is 79 percent of the ReNU syndrome burden in the 100KGP data.
The reason it went unnoticed has a specific answer: RNU2-2 was listed as a pseudogene until 2025. A pseudogene is a gene presumed to be non-functional — the molecular equivalent of a book with most of its pages torn out. No one was looking for disease-causing variants in a gene that was supposed to be broken.
"Prior to the recent identification of RNU gene-mediated NDDs by us, none of the five sets of snRNA paralogs related to the major spliceosome had been implicated in disease," Turro wrote. His team at Mount Sinai had to first demonstrate that RNU4-2 (which causes dominant ReNU syndrome) and RNU2-2 (which they initially found causes a less common dominant form) were disease genes at all. The May 2024 paper identifying RNU4-2 as the cause of ReNU syndrome was independently confirmed by a separate group using the same UK dataset. The dominant ReNU2 connection came in April 2025. The recessive form is March 2026. Turro's group has been building this story incrementally — two years, three papers.
The therapeutic thread is cautiously encouraging. Because unaffected carriers upregulate their working RNU2-2 copy to compensate, the body's own mechanism for protecting carriers from symptoms is potentially the same mechanism you would try to exploit in therapy. Introducing wild-type U2-2 RNA into the right cell types — neurons, not blood cells — could theoretically reduce seizures and improve developmental outcomes. Gene replacement for this disorder is not yet possible, but the path is clearer than it was before.
The Mount Sinai team is now enrolling families in the INDEED study to collect natural history data, establish clinical management guidelines, and build the foundation for future trials. A ReNU2 Syndrome Foundation has been established by affected families.
One caveat: the prevalence figures come from UK data. The global burden is uncertain, though the disorder has been confirmed in US, Italian, and Dutch cohorts. In populations with higher rates of consanguinity, the recessive form could be substantially more common. Most current genetic testing panels do not include RNU4-2 or RNU2-2, so many cases are likely being missed rather than diagnosed.
The statistical evidence, though, is not soft. A log Bayes factor of 18.2 from a method designed to detect both dominant and recessive inheritance, replicated across three independent patient collections in different countries, is not a number you argue with. What you argue about is what to do now that you know it exists.
The story of recessive ReNU2 syndrome is a story about what large genomic datasets can surface when you look at the right places with the right tools. A gene that was dismissed as junk. A disorder hiding in plain sight. The families who now have a name for what their children have — which, for many of them, is not a small thing.
